Guided Therapeutics partners with Türkiye Health Ministry on LuViva cervical cancer screening study
GTHP•Study funding and scope
The Ministry of Health will fund the six-month study, including purchases of LuViva devices and single-use Cervical Guides.
Potential rollout in Türkiye
Successful results could position LuViva to screen up to 20 million Turkish women annually with immediate results.
Guided Therapeutics partners with Türkiye Health Ministry
Guided Therapeutics reached a collaboration with Türkiye’s Ministry of Health to co-develop LuViva as a primary cervical cancer screening test.
The partnership begins with an 800-patient clinical study to refine AI pattern-recognition for real-time detection of early cellular changes.
